Home
Storia in 2 fonti
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label.
- ·
medpagetoday.com
Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma
- ·
endpoints.news
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used…